ALLO insider buying and SEC filings, explained
Allogene Therapeutics, Inc. · CIK 1737287
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$669K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 21, 2026 | Sale | Geoffrey M. Parker (CFO) sold 36,342 shares at $1.34 ($49K). Holdings down 3% to 1,045,877 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 23, 2026, 4:48 PM ET |
| Aug 21, 2026 | Sale | Earl Martin Douglas (SVP, General Counsel) sold 29,697 shares at $2.12 ($63K). Holdings down 6% to 488,267 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 25, 2026 |
| Apr 21, 2026 | Sale | Annie Yoshiyama (SVP, Finance) sold 9,586 shares at about $2.31 ($22K). Holdings down 7% to 124,517 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 23, 2026 |
| Mar 31, 2026 | Sale | Benjamin Machinas Beneski (SVP, Chief Technical Officer) sold 2,867 shares at $2.50 ($7K). Holdings down 1% to 195,338 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 2, 2026 |
| Mar 16, 2026 | Sale | Benjamin Machinas Beneski (SVP, Chief Technical Officer) sold 4,835 shares at about $2.47 ($12K). Holdings down 2% to 198,205 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Sale | David D Chang (CEO and Director) sold 47,763 shares at $2.47 ($118K). Holdings down 1% to 5,150,599 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 18, 2026 |
| Mar 2, 2026 | Sale | Benjamin Machinas Beneski (SVP, Chief Technical Officer) sold 7,132 shares at about $2.60 ($19K). Holdings down 3% to 203,040 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 2, 2026 | Sale | Benjamin Machinas Beneski (SVP, Chief Technical Officer) sold 7,549 shares at about $1.73 ($13K). Holdings down 3% to 210,172 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | David D Chang (CEO and Director) sold 95,269 shares at about $1.80 ($171K). Holdings down 2% to 5,185,862 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Geoffrey M. Parker (CFO) sold 24,001 shares at about $1.76 ($42K). Holdings down 2% to 1,252,795 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Annie Yoshiyama (SVP, Finance) sold 4,167 shares at about $1.72 ($7K). Holdings down 3% to 130,322 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Zachary Roberts (EVP of R&D) sold 35,700 shares at about $1.77 ($63K). Holdings down 6% to 581,166 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Feb 2, 2026 | Sale | Earl Martin Douglas (SVP, General Counsel) sold 22,900 shares at about $1.76 ($40K). Holdings down 4% to 564,948 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Jan 21, 2026 | Sale | Zachary Roberts (EVP of R&D) sold 26,269 shares at $1.56 ($41K). Holdings down 4% to 616,866 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Nov 17, 2025 | Sale | Benjamin Machinas Beneski (SVP, Chief Technical Officer) sold 786 shares at about $1.22 ($959). Holdings down <1% to 217,721 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
16 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ALLO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.